Corrigendum to ‘Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro’

Cook SE, Vogel H, Castillo D, et al. Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro. J Feline Med Surg 2022; 10: 943–953. DOI: 10.1177/1098612X211048647.

Readers should note that the version of the article that was published in the October 2022 issue contained typographical errors with regard to the EIDD nomenclature where, in several instances, it should have been EIDD2801 and EIDD1931 rather than EIDD2081 and EIDD2931, respectively. The version now appearing online is the correct one. For information, the following amendments have been made.

In the ‘Results’ section of the abstract, where it was previously ‘The most effective compounds include GC376, GS-441524, EIDD2081 and EIDD2931’ it is now ‘The most effective compounds include GC376, GS-441524, EIDD2801 and EIDD1931’. In the ‘Discussion’ on page 950, first paragraph, where it was previously ‘Based on the results of both the plaquing and viral RNA inhibition (RT-qPCR) assays, the most effective antiviral compounds that were identified include GC376, GS-441524, EIDD2081 and EIDD2931’ it is now ‘Based on the results of both the plaquing and viral RNA inhibition (RT-qPCR) assays, the most effective antiviral compounds that were identified include GC376, GS-441524, EIDD2801 and EIDD1931’.